Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Opdivo
Opdivo
Bristol Myers, overshadowed by ADC rival, wins FDA nod for Opdivo combo in bladder cancer
Fierce Pharma
Fri, 03/8/24 - 11:54 am
Bristol Myers Squibb
Opdivo
FDA
bladder cancer
Top 40 Best-Selling Oncology Drugs in 2023 by 2022 Data
Xtalks
Mon, 02/5/24 - 10:17 am
oncology
cancer
Keytruda
Revlimid
Opdivo
Imbruvica
Darzalex
Merck
Bristol Myers Squibb
AbbVie
Janssen
BMS' subcutaneous Opdivo clears first phase 3 trial
Pharmaphorum
Mon, 01/29/24 - 11:06 am
Bristol Myers Squibb
Opdivo
clinical trials
kidney cancer
subcutaneous Opdivo
BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer
BioSpace
Fri, 12/8/23 - 10:00 am
Bristol Myers Squibb
Opdivo
Yervoy
colorectal cancer
metastatic colorectal cancer
clinical trials
BMS chases Merck/Seagen with first-line bladder cancer filing
Pharmaphorum
Tue, 12/5/23 - 11:53 pm
Bristol Myers Squibb
Opdivo
bladder cancer
urothelial cancer
Merck
Seagen
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
BioSpace
Mon, 10/23/23 - 05:15 pm
ESMO
Merck
Bristol Myers Squibb
bladder cancer
PD-1 inhibitors
Keytruda
Padcev
Opdivo
ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow
Fierce Pharma
Sun, 10/22/23 - 06:06 pm
ESMO
Bristol Myers Squibb
Opdivo
bladder cancer
Padcev
Keytruda
Merck
BMS, Halozyme score with subcutaneous version of Opdivo
Fierce Pharma
Thu, 10/19/23 - 10:42 pm
Bristol Myers Squibb
Halozyme
Opdivo
clinical trials
Bristol Myers Squibb's Opdivo reign expands with new earlier-stage melanoma nod
Fierce Pharma
Mon, 10/16/23 - 11:45 am
Bristol Myers Squibb
Opdivo
melanoma
FDA
Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer
BioPharma Dive
Sun, 09/24/23 - 08:54 pm
Bristol Myers Squibb
Opdivo
non-small cell lung cancer
clinical trials
Bristol Myers gets positive opinion from CHMP for Opdivo
Pharmaceutical Business Review
Mon, 07/24/23 - 10:20 am
Bristol Myers Squibb
Opdivo
CHMP
Europe
melanoma
Bristol Myers' Opdivo stages comeback in bladder cancer, teeing up 2 'Merck' showdowns
Fierce Pharma
Wed, 07/12/23 - 09:30 am
Bristol Myers Squibb
Opdivo
bladder cancer
Merck
Sellas celebrates positive Phase I results in lung cancer
Clinical Trials Arena
Thu, 06/29/23 - 11:35 am
Sellas
clinical trials
immunotherapy
Opdivo
mesothelioma
lung cancer
ASCO: Seagen's top-selling drug under threat as Bristol Myers' Opdivo beats Adcetris in lymphoma
Fierce Pharma
Sun, 06/4/23 - 04:31 pm
ASCO 2023 - Seagen
Bristol Myers Squibb
Adcetris
Opdivo
antibody-drug conjugate
Hodgkin's lymphoma
Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again
Fierce Pharma
Tue, 05/2/23 - 11:30 pm
Bristol Myers Squibb
Opdivo
patents
legal
AstraZeneca
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
CP WIre
Sat, 03/18/23 - 03:37 pm
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Sat, 03/18/23 - 03:35 pm
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
Fierce Pharma
Fri, 03/10/23 - 11:20 am
Merck
Keytruda
Opdivo
Bristol Myers Squibb
pleural mseothelioma
mesothelioma
clinical trials
Bristol Myers axes German launch of new cancer drug, citing pricing hurdles
Endpoints
Tue, 03/7/23 - 10:37 pm
Bristol Myers Squibb
Germany
Opdivo
Opdualag
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
BioPharma Dive
Tue, 02/21/23 - 11:05 am
Big Pharma
patents
patent cliff
biosimilars
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Opdivo
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »